PD-1 immunotherapy with chemotherapy followed by immediate or delayed local radiation for newly metastatic nasopharyngeal cancer

A Multicenter, Open-Label, Randomized Phase III Non-Inferiority Trial of PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic Nasopharyngeal Carcinoma

This trial tests whether waiting to give local radiotherapy (only if needed) after PD‑1 immunotherapy plus gemcitabine‑cisplatin works as well and causes less toxicity than giving radiotherapy right away for people with newly diagnosed metastatic nasopharyngeal cancer who respond to initial treatment.

Quick facts

• Phase: Phase 3
• Study type: Interventional
• Enrollment: 260 (estimated)
• Ages: 18 Years to 70 Years
• Sex: All
• Sponsor: Sun Yat-sen University (Academic / other)
• Drugs / interventions: chemotherapy, immunotherapy
• Locations: 5 sites (Guangzhou, Guangdong and 4 other locations)
• Trial ID: NCT07235319 on ClinicalTrials.gov

What this trial studies

Adults with newly diagnosed (de novo) metastatic nasopharyngeal carcinoma receive first‑line PD‑1 inhibitor combined with gemcitabine and cisplatin (GP). Those who achieve a complete or partial response after 4–6 cycles are randomized in this phase III trial to immediate locoregional radiotherapy or to delayed (salvage) radiotherapy only if needed. The primary design is a non‑inferiority comparison focused on survival outcomes while monitoring treatment‑related toxicity. The trial is being conducted at major cancer centers in China.

Who should consider this trial

Good fit: Adults aged 18–70 with newly diagnosed de novo metastatic non‑keratinizing nasopharyngeal carcinoma, ECOG 0–1, measurable disease, adequate organ function, no prior anti‑tumor treatment, and who achieve a complete or partial response after 4–6 cycles of PD‑1 inhibitor plus GP.

Not a fit: Patients who do not respond to the initial PD‑1 plus GP regimen, have poor performance status, prior anti‑tumor therapy, or insufficient organ function are unlikely to be eligible or to benefit from the delayed‑radiotherapy approach.

Why it matters

Potential benefit: If successful, some patients could avoid immediate locoregional radiotherapy and its side effects without compromising survival.

How similar studies have performed: PD‑1 inhibitor plus gemcitabine‑cisplatin is established as first‑line therapy for metastatic NPC and some studies support locoregional radiotherapy, but the non‑inferiority of delayed (salvage) radiotherapy after immunochemotherapy has not been proven.

Eligibility criteria

Inclusion Criteria:

1. Age 18-70 years, any gender.
2. Histologically confirmed differentiated non-keratinizing carcinoma or undifferentiated non-keratinizing carcinoma by tissue biopsy, with radiologically detectable metastatic lesions. Pathological confirmation of metastatic lesions is recommended but not mandatory.
3. ECOG performance status 0-1.
4. Stage IV NPC according to the 9th edition of the UICC/AJCC staging system.
5. No prior anti-tumor treatment for NPC (radiotherapy, chemotherapy, surgery, etc.).
6. Expected survival ≥ 3 months.
7. At least one measurable lesion per RECIST v1.1.
8. Achieved complete response (CR) or partial response (PR) after 4-6 cycles of chemotherapy plus PD-1 inhibitor therapy.
9. Adequate organ function within 14 days before first dose, defined as:

   Hematology：Hemoglobin ≥ 90 g/L，ANC ≥ 1.5 × 10⁹/L，Platelet count ≥ 100 × 10⁹/L Renal Function：Creatinine ≤ 1.5 × ULN, or creatinine clearance (CrCl) / eGFR ≥ 60 mL/min Liver Function：Total bilirubin ≤ 1.5 × ULN，AST and ALT ≤ 2.5 × ULN, or ≤ 5 × ULN in the presence of liver metastases
10. INR or PT ≤ 1.5 × ULN, unless on therapeutic anticoagulation and values within therapeutic range，aPTT ≤ 1.5 × ULN, unless on therapeutic anticoagulation and values within therapeutic range

Exclusion Criteria:

1. Prior anti-tumor therapy for nasopharyngeal carcinoma, including radiotherapy, chemotherapy, surgery, or immunotherapy.
2. Prior treatment with PD-1/PD-L1 or CTLA-4 inhibitors.
3. Presence of uncontrolled or symptomatic central nervous system (CNS) metastases.
4. History of other malignancies within the past 5 years, except adequately treated basal cell carcinoma, squamous cell skin cancer, or in-situ cervical cancer.
5. Active autoimmune disease or history of autoimmune disease requiring systemic treatment (e.g., corticosteroids, immunosuppressants) within the past 2 years, except for stable hypothyroidism, type 1 diabetes mellitus, or resolved childhood asthma/atopy.
6. Known history of active pulmonary tuberculosis (TB). Suspected active TB must be excluded by chest X-ray, sputum examination, and assessment of clinical signs and symptoms.
7. Hepatitis B: HBsAg positive with peripheral blood HBV DNA ≥ 1000 copies/mL
8. Hepatitis C: HCV antibody positive, eligible only if HCV RNA is negative
9. HIV infection
10. Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, myocardial infarction within 6 months, congestive heart failure ≥ NYHA class II, or serious arrhythmia).
11. Interstitial lung disease, non-infectious pneumonitis, or history of ≥ grade 2 pneumonitis.
12. Major surgery within 4 weeks before enrollment, or unhealed surgical wound.
13. Pregnant or breastfeeding women, or those planning pregnancy during the study period.
14. Known allergy or hypersensitivity to study drugs or their excipients.
15. Any condition that, in the investigator's judgment, would interfere with trial participation or interpretation of results.

Where this trial is running

Guangzhou, Guangdong and 4 other locations

• Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (Recruiting)
• Hunan Cancer Hospital — Changsha, China (Not_yet_recruiting)
• Fujian Cancer Hospital — Fuzhou, China (Not_yet_recruiting)
• Zhejiang Cancer Hospital — Hangzhou, China (Not_yet_recruiting)
• Guangxi Medical University Cancer Hospital — Nanning, China (Not_yet_recruiting)

Study contacts

• Study coordinator: Haiqiang Mai, PhD, MD

Conditions Nasopharangeal Cancer; Distant Metastasis; Locoregional radiotherapy